Australia's most trusted
source of pharma news
Thursday, 11 September 2025
Posted 11 September 2025 AM
Novo Nordisk will reduce its global workforce by 9,000 as part of a company-wide transformation to simplify operations, speed decision-making and redirect resources to growing its obesity and diabetes business.
The bulk of the job losses, around 5000, will be in Denmark where the company is headquartered, but cuts are expected "across the company" delivering savings of around DKK8 billion (AU$1.9 billion) by the end of 2026.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.